Press Releases
CAS Medical Systems, Inc. Reports Second Quarter FOR IMMEDIATE RELEASE: Andrew E. Kersey, President and CEO of CASMED, stated, “I am pleased with the improvement in our results over the first quarter of 2008. Revenues have rebounded, gross margins have improved and we have achieved near break-even results despite our continued investments in FORE-SIGHT® sales and marketing, a key cornerstone to our future. Further, during the quarter the Company put in place multiple initiatives to improve results from operations while focusing additional resources in the area of FORE-SIGHT. “Our vital signs monitoring business, along with the blood pressure cuff accessories, have shown a marked increase in the second quarter. We are quite pleased with the momentum that these product lines are showing. In addition, sales of our OEM non-invasive blood pressure technology were strong. This product mix produced higher gross margins than those of the previous quarter. “We recently reported the installation of our 100th FORE-SIGHT Cerebral Oximeter, an important milestone for the Company as the product gains wider acceptance. The growth of the installed base has resulted in an acceleration of sales of the disposable sensors that are used with the monitor. In this first year of commercial release of the product, we believe we have captured 2% of the available U.S. Cardio-Vascular Operating Room market and expect that to increase as market awareness improves. Our sensor utilization per monitor continues to trend well with each monitor generating an average of approximately $1,700 of recurring sensor revenue per month. “CASMED has also recently announced the commercial launch and first sales of our Neonatal/Infant Sensors. This is an important market opportunity for us, with potential for monitoring neonatal patients throughout their length of stay in the hospital from the Neonatal ICU through the OR and Pediatric ICU settings. The absolute measurement technology offered by the FORE-SIGHT Cerebral Oximeter improves the quality of patient care, providing clinicians with real-time information regarding the balance of oxygen supply and demand in the brain tissue. CASMED’s already extensive experience in the neonatal marketplace, along with our positive clinical feedback from testing at various key hospitals, makes us uniquely positioned to take advantage of the neonatal/infant market opportunity.” Financial Results for Q2 For the three months ended June 30, 2008, the Company recorded a net loss of $32,000, or ($0.00) per basic and diluted common share, compared to a net loss of $301,000, or ($0.03) per basic and diluted common share, reported for the three months ended June 30, 2007. The improvement in the Company’s financial results compared to prior year is largely from increases in revenue and reductions in operating expenses as a percentage of sales. Increases in FORE-SIGHT sales and marketing related expenses significantly affected the Company’s second quarter operating results. FORE-SIGHT sales and marketing related expenses approximated $825,000 for the quarter compared to approximately $345,000 for the same period of the prior year. Stock compensation expense was $91,000 for the second quarter of 2008, compared to $37,000 for the same period of the prior year. Year-to-Date Financial Results The Company recorded a net loss of $562,000, or ($0.05) per basic and diluted common share, compared to a net loss of $221,000, or ($0.02) per basic and diluted common share, reported for the first six months of the prior year. Cost of sales as a percentage of sales for the first six months of 2008 increased to 68% from 65% during the same period of 2007 as a result of higher costs of sales in the first quarter of 2008. Increases in FORE-SIGHT sales and marketing related expenses significantly affected the Company’s year-to-date operating results. For the first six months of 2008 FORE-SIGHT sales and marketing related expenses approximated $1.5 million compared to approximately $800,000 for the same period of the prior year. As a result, year-to-date S,G&A expenses increased to over 31% of sales from nearly 29% of sales during the first six months of the prior year. Partially offsetting these increases were reductions in R&D spending. As a result, operating expenses as a percentage of sales remained at 36% for both periods reported. Stock compensation expense was $231,000 for the first six months of 2008, compared to $131,000 for the same period of the prior year. The Company’s income tax benefit of $66,000 for the first six months of 2008 assumes an effective tax rate of 46 percent as compared to an effective income tax rate of 33 percent for the same period of 2007 as a result of anticipated state and federal R&D tax credits. The Company has generated cash from operations during the first six months of 2008 of $334,000 compared to $1.4 million of cash used by operations during the same period of 2007. Bank debt levels have remained relatively unchanged on a year-to-date basis supported by a private placement of $1.0 million consummated during May 2008. Actual borrowings against the line-of-credit increased by $295,000 from December 31, 2007 to $2.5 million as of June 30, 2008, while long-term debt was reduced by $284,000 from December 31, 2007. 2008 Outlook Conference Call Information The live call may be accessed by phone at 877-548-7901 (domestic) or 719-325-4845 (international). If you would like to participate, please call at least ten minutes prior to the start time of 10:00 a.m. Eastern Time. A live audio webcast of the conference call will also be available on the Company's website located at www.casmed.com. Please allow extra time prior to the call to visit the site and download the streaming media software required to join the webcast. An online archive of the webcast will be available within two hours of the end of the live call and archived on the website until September 6, 2008. About CASMED® - Monitoring What’s Vital The Company’s product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; the bedside patient monitoring line of vital signs and cardio-respiratory monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates. For further information regarding CAS Medical Systems, Inc., visit the Company’s website at www.casmed.com. Company Contacts Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, commercialization and technological difficulties, the impact of actions and events involving key customers and vendors, and other risks detailed in the Company’s Form 10-K for the year ended December 31, 2007 and other subsequent Securities and Exchange Commission filings. Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.   |
